Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.

ABSTRACT:

Purpose

The study aimed to characterize the population pharmacokinetics of panobinostat, a pan-deacetylase inhibitor that has demonstrated efficacy in combination with bortezomib and dexamethasone in patients with multiple myeloma.

Methods

A nonlinear mixed-effect model was used to fit plasma panobinostat concentration-time data collected from patients across 14 phase 1 and phase 2 trials following either oral or intravenous (IV) administration. The model was used to estimate bioavailabilities of the two oral formulations and the effects of demographic and clinical covariates on the central volume of distribution and clearance of panobinostat.

Results

A total of 7834 samples from 581 patients were analyzed. Panobinostat pharmacokinetic parameters were best characteriz

SUBMITTER: Savelieva M 

PROVIDER: S-EPMC4430599 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature